Name Development Level Target Family
Complement C5 Tclin Non-IDG
Name Description
eculizumab a recombinant humanized monoclonal IgG2/4k antibody produced by murine myeloma cell culture, specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9
TCRDv4.6.0
DrugCentral Indication
DrugCentral
eculizumab